Pharming Group Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	158.28	145.31	54.94	61.74	207.34	191.92
Short-Term Investments	-	33.8	112.95	151.68	-	-
Cash & Short-Term Investments	158.28	179.1	167.89	213.42	207.34	191.92
Cash Growth	25.61%	6.68%	-21.33%	2.93%	8.03%	-6.45%
Accounts Receivable	56.98	54.7	54.82	46.16	27.62	29.98
Inventory	65.43	64.9	55.72	56.76	42.33	27.31
Other Current Assets	-	0.76	-	-	0.21	0.23
Total Current Assets	280.69	299.47	278.44	316.34	277.5	249.44
Net Property, Plant & Equipment	20.48	23.97	24.13	33.47	39.15	33.17
Other Intangible Assets	128.08	135.54	61.04	71.27	75.12	83.83
Long-Term Investments	8.58	8.65	4.23	10.4	9.73	8.65
Other Long-Term Assets	30.16	32.34	32.14	31.38	24.3	22.22
Total Assets	467.98	499.96	399.99	462.85	425.8	397.32
Accounts Payable	82.32	105.9	66.61	72.53	54.47	42.47
Current Portion of Long-Term Debt	5.47	5.34	4.25	1.82	1.77	1.88
Current Portion of Leases	3.58	3.37	2.95	3.62	3.47	2.42
Other Current Liabilities	1.88	1.19	-	-	-	-
Total Current Liabilities	93.25	115.79	73.8	77.97	59.7	46.77
Long-Term Debt	92.4	92.72	78.15	136.6	131.62	139.17
Long-Term Leases	11.85	14.35	26.97	29.51	29.84	18.46
Total Long-Term Liabilities	104.25	107.07	105.12	166.11	161.46	157.63
Total Liabilities	197.49	222.86	178.92	244.07	221.16	204.4
Common Stock	8.08	8.01	7.77	7.67	7.51	7.43
Additional Paid-in Capital	520.31	513.26	488.99	478.43	462.3	455.25
Accumulated Other Comprehensive Income	20.34	28.82	-0.21	-2.06	-8.74	3.4
Retained Earnings	-278.25	-272.98	-275.49	-265.26	-256.43	-273.17
Shareholders' Equity	270.49	277.1	221.06	218.78	204.64	192.92
Total Liabilities & Equity	467.98	499.96	399.99	462.85	425.8	397.32
Total Debt	113.3	115.78	112.31	171.55	166.69	161.93
Net Cash (Debt)	44.99	63.33	55.58	41.88	40.65	30
Net Cash Growth	-	13.94%	32.72%	3.03%	35.50%	66.77%
Net Cash Per Share	0.60	0.85	0.71	0.58	0.57	0.43
Book Value	270.49	277.1	221.06	218.78	204.64	192.92
Book Value Per Share	3.61	3.71	2.81	3.02	2.89	2.75
Tangible Book Value	142.41	141.56	160.02	147.51	129.52	109.08
Tangible Book Value Per Share	1.90	1.90	2.04	2.03	1.83	1.56

SEC Filings: 10-K · 10-Q